Literature DB >> 18441665

Toward a Hippocratic psychopharmacology.

S Nassir Ghaemi1.   

Abstract

OBJECTIVE: To provide a conceptual basis for psychopharmacology.
METHOD: This review compares contemporary psychopharmacology practice with the Hippocratic tradition of medicine by examining the original Hippocratic corpus and modern interpretations (by William Osler and Oliver Wendell Holmes).
RESULTS: The Hippocratic philosophy is that only some, not all, diseases should be treated and, even then, treatments should enhance the natural healing process, not serve as artificial cures. Hippocratic ethics follow from this philosophy of disease and treatment. Two rules for Hippocratic medicine are derived from the teachings of Osler (treat diseases, not symptoms) and Holmes (medications are guilty until proven innocent). The concept of a diagnostic hierarchy is also stated explicitly: Not all diseases are created equal. This idea helps to avoid mistaking symptoms for diseases and to avoid excessive diagnosis of comorbidities. Current psychopharmacology is aggressive and non-Hippocratic: symptom-based, rather than disease oriented; underemphasizing drug risks; and prone to turning symptoms into diagnoses. These views are applied to bipolar disorder.
CONCLUSIONS: Contemporary psychopharmacology is non-Hippocratic. A proposal for moving in the direction of a Hippocratic psychopharmacology is provided.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18441665     DOI: 10.1177/070674370805300309

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  2 in total

Review 1.  Using Evolutionary Theory to Guide Mental Health Research.

Authors:  Zachary Durisko; Benoit H Mulsant; Kwame McKenzie; Paul W Andrews
Journal:  Can J Psychiatry       Date:  2016-02-12       Impact factor: 4.356

Review 2.  Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

Authors:  Alexander C Tsai; Nicholas Z Rosenlicht; Jon N Jureidini; Peter I Parry; Glen I Spielmans; David Healy
Journal:  PLoS Med       Date:  2011-05-03       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.